{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:44:49Z","timestamp":1786985089241,"version":"build-2736575974"},"reference-count":97,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.beem.2023.101746","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T11:12:12Z","timestamp":1676113932000},"page":"101746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Supporting evidence for lipoprotein(a) measurements in clinical practice"],"prefix":"10.1016","volume":"37","author":[{"given":"Anastasiya","family":"Matveyenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Pavlyha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gissette","family":"Reyes-Soffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2023.101746_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0014-5793(83)80182-3","article-title":"Protein composition of Lp(a) lipoprotein from human plasma","volume":"154","author":"Utermann","year":"1983","journal-title":"FEBS Lett"},{"key":"10.1016\/j.beem.2023.101746_bib2","first-page":"369","article-title":"A new serum type system in man-the LP system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol\u00a0Microbiol\u00a0Scand"},{"key":"10.1016\/j.beem.2023.101746_bib3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/ATVBAHA.121.317335","article-title":"Apo(a) and ApoB interact noncovalently within hepatocytes: implications for regulation of Lp(a) levels by modulation of ApoB secretion","volume":"42","author":"Youssef","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2023.101746_bib4","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/S0022-2275(20)37461-7","article-title":"Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans","volume":"37","author":"Marcovina","year":"1996","journal-title":"J Lipid Res"},{"key":"10.1016\/j.beem.2023.101746_bib5","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehx033","article-title":"Lipoprotein(a): the revenant","volume":"38","author":"Gencer","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2023.101746_bib6","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/BF00282175","article-title":"The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen","volume":"79","author":"Frank","year":"1988","journal-title":"Hum Genet"},{"key":"10.1016\/j.beem.2023.101746_bib7","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1016\/j.jprot.2011.07.008","article-title":"Proteomics of lipoprotein(a) identifies a protein complement associated with response to wounding","volume":"74","author":"von Zychlinski","year":"2011","journal-title":"J Proteom"},{"key":"10.1016\/j.beem.2023.101746_bib8","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1194\/jlr.R077693","article-title":"The metabolism of lipoprotein (a): an ever-evolving story","volume":"58","author":"Reyes-Soffer","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.beem.2023.101746_bib9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/01.ATV.12.3.302","article-title":"Apolipoprotein (a) alleles determine lipoprotein (a) particle density and concentration in plasma","volume":"12","author":"Kraft","year":"1992","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.beem.2023.101746_bib10","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Pare","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2023.101746_bib11","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/ATVBAHA.117.309549","article-title":"CETP (Cholesteryl Ester Transfer Protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects","volume":"37","author":"Thomas","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2023.101746_bib12","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1194\/jlr.P082834","article-title":"Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects","volume":"59","author":"Nandakumar","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.beem.2023.101746_bib13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2023.101746_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154221","article-title":"PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)","volume":"107","author":"Watts","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.beem.2023.101746_bib15","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/clinchem\/38.11.2244","article-title":"Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure","volume":"38","author":"Oida","year":"1992","journal-title":"Clin Chem"},{"key":"10.1016\/j.beem.2023.101746_bib16","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0022-2275(20)37150-9","article-title":"Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation","volume":"38","author":"Kronenberg","year":"1997","journal-title":"J Lipid Res"},{"key":"10.1016\/j.beem.2023.101746_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.beem.2023.101746_bib18","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.beem.2023.101746_bib19","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms","volume":"58","author":"Mack","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.beem.2023.101746_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1161\/ATVBAHA.107.153981","article-title":"Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study","volume":"28","author":"Shiffman","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2023.101746_bib21","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1161\/ATVBAHA.107.141291","article-title":"A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease","volume":"27","author":"Luke","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2023.101746_bib22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2023.101746_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11789-019-00093-5","article-title":"Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region","volume":"14","author":"Kronenberg","year":"2019","journal-title":"Clin Res Cardiol Suppl"},{"key":"10.1016\/j.beem.2023.101746_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2023.101746_bib25","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1194\/jlr.P091249","article-title":"Heritability of apolipoprotein (a) traits in two-generational African-American and Caucasian families","volume":"60","author":"Enkhmaa","year":"2019","journal-title":"J Lipid Res"},{"key":"10.1016\/j.beem.2023.101746_bib26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2023.101746_bib27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/01.ATV.16.3.471","article-title":"Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study","volume":"16","author":"Schreiner","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2023.101746_bib28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jacc.2020.06.040","article-title":"Lipoprotein(a) and family history predict cardiovascular disease risk","volume":"76","author":"Mehta","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.beem.2023.101746_bib29","article-title":"Lipoprotein(a) and subclinical vascular and valvular calcification on cardiac computed tomography: the atherosclerosis risk in communities study","volume":"11","author":"Obisesan","year":"2022","journal-title":"J\u00a0Am\u00a0Heart Assoc"},{"key":"10.1016\/j.beem.2023.101746_bib30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","article-title":"Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk","volume":"79","author":"Mehta","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.beem.2023.101746_bib31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0026-0495(98)90217-7","article-title":"Elevated lipoprotein(a) levels in South Asians in North America","volume":"47","author":"Anand","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.beem.2023.101746_bib32","article-title":"Lipoprotein(a) and cardiovascular disease prevention across diverse populations","author":"Pearson","year":"2020","journal-title":"Cardiol\u00a0Ther"},{"key":"10.1016\/j.beem.2023.101746_bib33","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/ATVBAHA.114.304785","article-title":"Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the multi-ethnic study of atherosclerosis","volume":"35","author":"Guan","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2023.101746_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/nu12072024","article-title":"Diet and Lp(a): does dietary change modify residual cardiovascular risk conferred by Lp(a)?","volume":"12","author":"Enkhmaa","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.beem.2023.101746_bib35","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/01.ATV.18.3.441","article-title":"Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1","volume":"18","author":"Ginsberg","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2023.101746_bib36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/ajcn\/nqab287","article-title":"Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia-a randomized controlled feeding trial","volume":"115","author":"Ebbeling","year":"2022","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.beem.2023.101746_bib37","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1373\/clinchem.2010.146779","article-title":"Lipoprotein(a) and risk of type 2 diabetes","volume":"56","author":"Mora","year":"2010","journal-title":"Clin Chem"},{"key":"10.1016\/j.beem.2023.101746_bib38","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2023.101746_bib39","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.beem.2023.101746_bib40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0022-2275(20)42092-9","article-title":"Quantification of apo[a] and apoB in human atherosclerotic lesions","volume":"32","author":"Pepin","year":"1991","journal-title":"J Lipid Res"},{"key":"10.1016\/j.beem.2023.101746_bib41","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0022-2275(20)39699-1","article-title":"Partial characterization of lipoproteins containing apo[a] in human atherosclerotic lesions","volume":"34","author":"Hoff","year":"1993","journal-title":"J Lipid Res"},{"key":"10.1016\/j.beem.2023.101746_bib42","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2023.101746_bib43","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2023.101746_bib44","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.beem.2023.101746_bib45","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a Mendelian randomisation analysis","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2023.101746_bib46","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2023.101746_bib47","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2023.101746_bib48","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1210\/jc.2015-1096","article-title":"Elevated lipoprotein(a) does not cause low-grade inflammation despite causal association with aortic valve stenosis and myocardial infarction: a study of 100,578 individuals from the general population","volume":"100","author":"Langsted","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101746_bib49","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/14779072.2017.1367286","article-title":"Pathobiology of Lp(a) in calcific aortic valve disease","volume":"15","author":"Mathieu","year":"2017","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.beem.2023.101746_bib50","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.jacc.2019.02.039","article-title":"Lp(a) oxyphospholipids: markers and mediators of vascular mineral metabolism in calcific aortic valve disease","volume":"73","author":"Towler","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.beem.2023.101746_bib51","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.beem.2023.101746_bib52","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2023.101746_bib53","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2023.101746_bib54","first-page":"31","article-title":"The association of lipoprotein(a) and apolipoprotein(a) phenotypes with peripheral artery disease","volume":"90","author":"Tmoyan","year":"2018","journal-title":"Ter Arkh"},{"key":"10.1016\/j.beem.2023.101746_bib55","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0021-9150(00)00719-X","article-title":"Lipoprotein (a) and development of intermittent claudication and major cardiovascular events in men and women: the Edinburgh Artery Study","volume":"157","author":"Price","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.beem.2023.101746_bib56","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/MOL.0000000000000779","article-title":"The iterative lipid impact on inflammation in atherosclerosis","volume":"32","author":"Kraaijenhof","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.beem.2023.101746_bib57","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1161\/CIRCRESAHA.119.316206","article-title":"Atherogenic lipoprotein(a) increases vascular glycolysis, thereby facilitating inflammation and leukocyte extravasation","volume":"126","author":"Schnitzler","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.beem.2023.101746_bib58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2022.07.015","article-title":"Lipoprotein(a) during COVID-19 hospitalization: Thrombosis, inflammation, and mortality","volume":"357","author":"Kaltoft","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.beem.2023.101746_bib59","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.beem.2023.101746_bib60","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2023.101746_bib61","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz748.0165","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1beta inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","author":"Ridker","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2023.101746_bib62","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2023.101746_bib63","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/01.CIR.0000020546.30940.92","article-title":"Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina","volume":"106","author":"Blankenberg","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2023.101746_bib64","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1194\/jlr.P052209","article-title":"IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans","volume":"56","author":"Muller","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.beem.2023.101746_bib65","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jamacardio.2020.2413","article-title":"Effect of C-reactive protein on lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-risk vascular disease: a prespecified secondary analysis of the ACCELERATE trial","volume":"5","author":"Puri","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.beem.2023.101746_bib66","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jacc.2021.07.016","article-title":"High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a): multi-ethnic study of atherosclerosis","volume":"78","author":"Zhang","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.beem.2023.101746_bib67","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.beem.2023.101746_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105689","article-title":"Beyond lipoprotein(a) plasma measurements: lipoprotein(a) and inflammation","volume":"169","author":"Reyes-Soffer","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.beem.2023.101746_bib69","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/HCO.0000000000000300","article-title":"Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis","volume":"31","author":"Yeang","year":"2016","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.beem.2023.101746_bib70","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jacl.2018.11.003","article-title":"JCL roundtable-Lipoprotein(a): the emerging risk factor","volume":"12","author":"Marcovina","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.beem.2023.101746_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","author":"Tsimikas","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.beem.2023.101746_bib72","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1054\/ghir.2000.0134","article-title":"Changes in lipoprotein(a) levels measured by six kit methods during growth hormone treatment of growth hormone-deficient adults","volume":"10","author":"Wieringa","year":"2000","journal-title":"Growth Hormone\u00a0IGF Res"},{"key":"10.1016\/j.beem.2023.101746_bib73","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1007079223546","article-title":"Evaluation of a new apolipoprotein(a) isoform-independent assay for serum lipoprotein(a)","volume":"207","author":"Dembinski","year":"2000","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.beem.2023.101746_bib74","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working Group Recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.beem.2023.101746_bib75","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.beem.2023.101746_bib76","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.beem.2023.101746_bib77","first-page":"8","article-title":"Lipid association of India expert consensus statement on management of dyslipidemia in Indians 2020: Part III","volume":"68","author":"Puri","year":"2020","journal-title":"J Assoc Phys\u00a0India"},{"key":"10.1016\/j.beem.2023.101746_bib78","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.acvd.2021.10.009","article-title":"Lipoprotein(a): pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Societe Francophone d'Atherosclerose (NSFA)","volume":"114","author":"Durlach","year":"2021","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.beem.2023.101746_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100371","article-title":"There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness","volume":"12","author":"Makover","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.beem.2023.101746_bib80","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2023.101746_bib81","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11883-020-00886-0","article-title":"Therapeutic apheresis for management of Lp(a) hyperlipoproteinemia","volume":"22","author":"Pokrovsky","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.beem.2023.101746_bib82","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.atherosclerosissup.2017.05.009","article-title":"Rationale and design of MultiSELECt: a European multicenter study on the effect of lipoprotein(a) elimination by lipoprotein apheresis on Cardiovascular outcomes","volume":"30","author":"Hohenstein","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.beem.2023.101746_bib83","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5339\/gcsp.2014.3","article-title":"The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina","volume":"2014","author":"Khan","year":"2014","journal-title":"Glob Cardiol Sci Pract"},{"key":"10.1016\/j.beem.2023.101746_bib84","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/eurheartj\/ehx178","article-title":"Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial","volume":"38","author":"Khan","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2023.101746_bib85","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2023.101746_bib86","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2023.101746_bib87","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa672","article-title":"Treatment of thyroid dysfunction and serum lipids: a systematic review and meta-analysis","volume":"105","author":"Kotwal","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101746_bib88","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/01.ATV.13.2.296","article-title":"Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations","volume":"13","author":"Eden","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.beem.2023.101746_bib89","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0026-0495(86)90150-2","article-title":"Fluctuations of plasma lipoprotein-A concentrations during pregnancy and post partum","volume":"35","author":"Zechner","year":"1986","journal-title":"Metabolism"},{"key":"10.1016\/j.beem.2023.101746_bib90","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1463-1326.2005.00545.x","article-title":"Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women","volume":"8","author":"Salpeter","year":"2006","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.beem.2023.101746_bib91","first-page":"234","article-title":"Causes and consequences of lipoprotein(a) abnormalities in kidney disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin\u00a0Exp\u00a0Nephrol"},{"key":"10.1016\/j.beem.2023.101746_bib92","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/480784","article-title":"A systematic literature review of the association of lipoprotein(a) and autoimmune diseases and atherosclerosis","volume":"2012","author":"Missala","year":"2012","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.beem.2023.101746_bib93","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working Group Recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.beem.2023.101746_bib94","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of lipoprotein(a) in clinical practice: a\u00a0biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.beem.2023.101746_bib95","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Authors\/Task Force M","year":"2019","journal-title":"Atherosclerosis"},{"issue":"41","key":"10.1016\/j.beem.2023.101746_bib96","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2023.101746_bib97","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa674","article-title":"Lipid management in patients with endocrine disorders: an endocrine society clinical practice guideline","volume":"105","author":"Newman","year":"2020","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X23000155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X23000155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:59:47Z","timestamp":1761497987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X23000155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1521690X23000155"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2023.101746","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Supporting evidence for lipoprotein(a) measurements in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2023.101746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101746"}}